Screening
Asymptomatic patients are not routinely screened.
In the future, as neuroprotective agents are developed, at-risk populations may be screened. This would include those with family history or other significant risk factors such as rapid eye movement sleep behavior disorder. The use of dopamine transporter imaging with FP-CIT or beta-CIT single photon emission computed tomography (SPECT) and/or 18F-dopa positron emission tomography (PET) may enable identification of preclinical PD, but effectiveness for screening has not yet been established.[79]
Use of this content is subject to our disclaimer